Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries
04:05pm, Tuesday, 25'th Mar 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now cove
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
07:51am, Thursday, 13'th Mar 2025
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently ge
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
02:48pm, Tuesday, 11'th Mar 2025
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (C
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Friday, 28'th Feb 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insight
Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 25'th Feb 2025
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
01:33pm, Friday, 21'st Feb 2025
On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents.
Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript
11:14pm, Thursday, 20'th Feb 2025
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR H
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
07:30pm, Thursday, 20'th Feb 2025
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
06:40pm, Thursday, 20'th Feb 2025
Guardant Health (GH) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.58 per share a year ago.
Guardant Health Tops Q4 Revenue Forecast
05:54pm, Thursday, 20'th Feb 2025
Guardant Health (GH -3.26%), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' conse
Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS
10:20am, Monday, 17'th Feb 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:07am, Thursday, 13'th Feb 2025
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Thursday, 13'th Feb 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
09:45am, Thursday, 13'th Feb 2025
Blood-based cancer testing presents a large opportunity, that is now being realized, with the proliferation of MRD and screening tests. While there is significant competition, and the market winners a
